Journal article
Plasma amyloid-β levels are significantly associated with a transition toward alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden
A Rembach, AD Watt, WJ Wilson, VL Villemagne, SC Burnham, KA Ellis, P Maruff, D Ames, CC Rowe, SL MacAulay, AI Bush, RN Martins, CL Masters, JD Doecke
Journal of Alzheimer S Disease | IOS PRESS | Published : 2014
DOI: 10.3233/JAD-131802
Abstract
Background: We evaluated the utility of longitudinal measures of plasma amyloid-β (Aβ) as a means to identify pre-symptomatic cognitive decline in Alzheimer's disease (AD) when coupled to neuroimaging and neuropsychological parameters. Methods: Participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study were grouped based upon cognitive change and changes in measurable levels of neocortical amyloid over 36 months. Participants were classified as those who transitioned for cognitive decline and change in neocortical amyloid, those healthy controls that did not transition, and stable AD participants over 36 months. Results: Comparisons of plasma Aβ levels between the transi..
View full abstractRelated Projects (1)
Grants
Funding Acknowledgements
This research was also supported by the Science Industry and Endowment Fund (http://www.sief.org.au/), and the National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DCRC2) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (http://www.aibl.csiro.au/). MHRI acknowledges the funding support from the Victorian Government's Operational Infrastructure Support program. Pfizer International has contributed financial support to assist with analysis of blood samples and to further the AIBL research program. The McCusker Foundation has contributed financial and in-kind support to AIBL.